The firm plans to release a research-use-only version of its test by the end of the year, and is still hoping for FDA clearance in 2019.
Nohla will use Karius' NGS plasma test for pathogen detection in a randomized trial evaluating Nohla's lead product, a cellular therapy called NLA101.
Sensitivity problems with rapid antigen tests are also helping the more accurate rapid molecular tests gain wider acceptance, manufacturers said.
An Institut Pasteur-Paris-led team analyzed genetic variants among individuals with classic dengue fever or dengue shock syndrome.
An analysis of metagenomic sequences from donor and recipient stool samples highlighted bacterial abundance, phylogeny, and strain features influencing engraftment.
OpGen recently launched the first Acuitas test, which is designed to detect the most common bacterial causes of complicated urinary tract infections.
The test runs on the BD Viper LT system and detects 14 high-risk types of human papilloma virus.
Luminex said that its MDx sample-to-answer portfolio grew 31 percent over the prior-year quarter and generated $12.9 million.
Overall, revenues were up 8 percent. In the diagnostics segment, molecular product sales were driven primarily by continued strength across Aptima women's health products.
Private equity firm Quadria Capital led the investment round and was joined by HealthQuad Fund and Heritas Venture Fund.
The Sentosa SA201 HSV-1/2 PCR test detects herpes virus DNA from oral or anal skin lesions in symptomatic patients.
Launch Diagnostics will distribute BioGx's entire product line, including laboratory-use-only products, in the UK and Ireland.
Researchers identified and began characterizing carbapenemase-producing bacteria from wastewater samples in ICU pipes and other sites at an NIH hospital.
The firm said it will use the net proceeds for R&D, including the continued development of its Acuitas AMR gene panels.
Designed to run on the company's Sentosa real-time PCR system, the test has been approved for identifying and differentiating Zika in patients.
The proposed diagnostic platform will be able to identify and determine resistance of bloodstream infections within three hours.
The company recently demonstrated the potential of its PCR and NGS assays to diagnose infections in patients' prosthetic knees and hips.
The PCR-based cartridge is designed to detect 21 pneumonia pathogens and 19 genetic markers of antibiotic resistance, and runs on the company's Unyvero system.
AxonLab will distribute BioGx's entire product line, including laboratory-use-only products, in central European countries.
Qiagen believes the flexibility of the Stat-Dx platform for an evolving reimbursement landscape will set it apart from other similar commercial platforms.
An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.
The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.
Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.
In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.